Biblio
Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience. Am J Hematol. 2023.
Synergistic cytotoxicity of fludarabine, clofarabine, busulfan, vorinostat and olaparib in AML cells. Front Oncol. 2023;13:1287444.
. ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells. Oncotarget. 2024;15:220-231.
. Comparison of whole-genome and immunoglobulin-based circulating tumor DNA assays in diffuse large B-cell lymphoma. Hemasphere. 2024;8(4):e47.
Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study. Am J Hematol. 2024.
Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation. Br J Haematol. 2024.
Incidence and Risk Factors of Early Onset VOD/SOS Differ in Younger vs Older Adults After Stem Cell Transplantation. Blood Adv. 2024.
Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation. Blood Cancer J. 2024;14(1):82.
Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience. Blood Cancer J. 2024;14(1):4.
Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis. Bone Marrow Transplant. 2024.
.